Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Colorectal Neoplasms 105Carcinoma, Hepatocellular 34Neoplasm Metastasis 19Neoplasms 17Gastrointestinal Stromal Tumors 17Colonic Neoplasms 14Rectal Neoplasms 12Liver Neoplasms 8Glioblastoma 7Sarcoma 6Stomach Neoplasms 5Sarcoma, Ewing 5Ovarian Neoplasms 5Osteosarcoma 5Melanoma 5Adenocarcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 3Rhabdomyosarcoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Leukemia, Myeloid, Acute 3Colorectal Cancer Metastatic 3Carcinoma, Transitional Cell 3Carcinoma 3Advanced Colorectal Cancer 3Thyroid Neoplasms 2

Interventions

Azacitidine 5venetoclax 4Specimen Handling 3Nivolumab 2regorafenib 1midostaurin 1iadademstat 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Vorinostat 1Thiotepa 1Tacrolimus 1Methotrexate 1Lenalidomide 1Injections 1Decitabine 1Cytarabine 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
GATA2 Deficiency × regorafenib × Clear all
NCT06454409 2025-11-19

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Medical Center

Phase 1 Suspended
20 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡